Adult Psychiatry· 7 min read
GLP-1 and Alcohol: Do They Really Cut Drinking?
For some heavy drinkers, a GLP-1 quiets the drinking along with the weight. It works mostly in the ones who are also overweight, but the research on GLP-1 and alcohol is only a couple of years old.
The strongest evidence is a 2026 randomized trial in the Lancet. It assigned 108 adults with alcohol use disorder and obesity to semaglutide or placebo, both alongside therapy, and heavy drinking days fell about 41 percentage points on semaglutide against 26 on placebo, a treatment difference near 14 points (Klausen, 2026). It was the first well-built trial to change how much people drank, and every patient in it had obesity.
The rest of the research runs the same way, unevenly. A 48-person study found low-dose semaglutide cut craving and lab drinking but not the number of drinking days (Hendershot, 2025). An earlier trial of exenatide, a first-generation GLP-1, missed its primary target across 127 patients yet worked in the subgroup who also had obesity (Klausen, 2022). In a Swedish registry of 227,866 people with alcohol use disorder, semaglutide tracked with fewer alcohol-related hospitalizations, a hazard ratio of 0.64, a larger drop than the approved addiction medications in the same data (Lähteenvuo, 2025). Those are registry associations, so they support the case without proving it.
I was watching this before the trials landed. Patients I’d started on a GLP-1 for weight kept telling me alcohol had lost its pull, and my own circles and the biohacker world were on it well before mainstream psychiatry. The literature has caught up to the anecdote.
How GLP-1 and Alcohol Are Connected
Alcohol drives the brain’s reward circuitry, the dopamine signaling that marks something as worth repeating. GLP-1 receptors sit in those same reward regions, the ventral tegmental area and nucleus accumbens, and in animals these drugs blunt drug intake and the dopamine release that reinforces it (Marquez-Meneses, 2025). My read is that they turn the reward down, so the drink delivers less payoff and the pull to keep going fades. Patients say alcohol stops doing much for them. The wider picture of how these drugs touch mood and the brain is in GLP-1 medications and mental health.
That same dopamine-driven reward system is dysregulated in ADHD, which I unpack in the neuroscience of ADHD.
Compare it with the medication we already use for this. Naltrexone blunts alcohol’s reward too, but only while it’s on board, so stopping it stops the effect. My suspicion is a GLP-1 may reshape the response in a way that lasts a little longer. That’s a hypothesis, and the weight people regain after stopping is a fair reason to doubt the drinking benefit simply holds. The trial that would settle it hasn’t been run.
Which GLP-1, and What Hasn’t Been Tested
The drinking trials used semaglutide and exenatide, which are not the strongest GLP-1s available. Semaglutide is the weakest of the current options for weight. Tirzepatide adds a second receptor and does more, and the triple agonist retatrutide does more still, though it isn’t approved yet. I lay out the differences in the comparison of the three GLP-1 generations.
The mechanism runs through the GLP-1 receptor that all of these drugs hit, so a class effect is plausible. Nobody has tested tirzepatide or retatrutide for drinking, though. The receptor is shared, but the only human evidence sits with the weaker agents. Anyone selling the newest shot as the answer for drinking is ahead of the data.
Who It Fits
The people it fits best carry excess weight and drink more than they want to. For a patient at a healthy weight, the proven medications come first. Oral naltrexone and acamprosate carry decades of trials. Naltrexone prevents one return to heavy drinking for roughly every 11 people treated, and acamprosate does the same for any return to drinking (McPheeters, 2023). I prescribe both. Reaching for a weight-loss drug in someone who doesn’t need to lose weight, to treat drinking, is hard to justify today.
The overweight-and-drinking combination is common, and it usually gets split between two clinicians who never compare notes. It sits in the metabolism-and-addiction overlap I write about in metabolic psychiatry, and whether the weight loss itself lifts mood is covered in weight loss and depression. Treated together, a GLP-1 can pull weight down and quiet the drinking at once, and where it isn’t enough alone it layers with the standard alcohol medications. Fatty liver often rides along in this group, and the same drug is being studied for it. A 2025 phase 3 trial improved the disease on biopsy (Sanyal, 2025).
How I Treat Weight and Drinking Together in North Carolina
I handle both sides of this in one place. For the right patient that means a GLP-1 for weight and the metabolic picture, the established medications for alcohol use when they’re warranted, and I watch whether the off-label benefit actually shows up. No GLP-1 is approved for drinking. I say that up front, and we work from the evidence we have. My job is to match the treatment to the patient and keep watching it, not write a prescription and move on.
If you are overweight and your drinking has crept past where you want it, it’s worth a conversation. You can book an appointment or call (910) 612-6015.
Frequently Asked Questions
Do GLP-1 medications reduce drinking?
The early evidence says they can, mostly in people who also carry excess weight. A 2026 Lancet trial found semaglutide cut heavy drinking days in adults with alcohol use disorder and obesity, by roughly 14 percentage points more than placebo (Klausen, 2026), and registry data agrees. No GLP-1 is FDA-approved for drinking, so this is off-label and still emerging.
How would a GLP-1 lower alcohol cravings?
GLP-1 receptors sit in the brain’s reward regions, and in animal studies these drugs blunt the dopamine signaling that reinforces intake (Marquez-Meneses, 2025). The likely result is that a drink delivers less payoff, so the pull to keep drinking fades. The human mechanism is still being worked out, but it fits what patients report.
Is Ozempic the best GLP-1 for this?
It is simply the one that got studied. Semaglutide is the weakest of the current GLP-1s for weight, and the drinking trials used it and exenatide. The stronger agents, tirzepatide and retatrutide, have not been tested for alcohol, though the shared receptor makes a class effect plausible. Which drug fits depends on the whole clinical picture.
Should I take a GLP-1 instead of naltrexone for drinking?
If you are at a healthy weight, the proven medications like naltrexone and acamprosate come first, with far stronger evidence. A GLP-1 makes the most sense when you also need to lose weight, where it may help both at once, and it can be combined with the standard medications. That decision belongs with a prescriber who knows your history.
Weight and Drinking, Treated Together
Dr. Baghel is a board-certified psychiatrist (ABPN) treating weight and alcohol use together for adults across North Carolina, by telehealth. Currently accepting new patients.
Or call (910) 612-6015
This article is for education, not medical advice. GLP-1 use for alcohol is off-label and emerging; decisions belong with a qualified clinician who knows your history. If you’re in crisis, call or text 988. The monthly plan covers Dr. Baghel’s clinical services only; labs and medications are billed separately.
References
- Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026;407(10540):1687-1698. PMID: 42070571.
- Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405. PMID: 39937469.
- Klausen MK, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19):e159863. PMID: 36066977.
- Lähteenvuo M, et al. Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. 2025;82(1):94-98. PMID: 39535805.
- Marquez-Meneses JD, et al. GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives. Int J Mol Sci. 2025;26(11):5338. PMID: 40508146.
- McPheeters M, et al. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023;330(17):1653-1665. PMID: 37934220.
- Sanyal AJ, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. PMID: 40305708.